FDA Investigator Vijaya L Simhadri
Vijaya L Simhadri has conducted inspections on 4 sites in 1 countries as of 28 Feb 2024. See below for a list of the FDA enforcement documents resulting from those inspections.
Investigator Details
Number of Inspected Sites:
4
Last Inspection Date:
28 Feb 2024
Investigator Role:
FDA Investigator
Redica ID:
Countries of Inspections:
United States of America
FDA Investigators that have inspected at least one site in common with Vijaya L Simhadri:
Alicia Gilbert,
Andrew C Chang,
Ann Marie Montemurro,
Ann Marie Schofield,
Binh T Nguyen,
Bo Chi, PhD,
Brenda W Uratani, PhD,
Candace Y Gomez Broughton,
Carl Lee,
Christian D Lynch (CDL),
Christopher R Czajka,
Cynthia Jim, CSO,
Daniel Lagasse,
Deborah M Trout,
Decarlos A Gomez,
Donald C Obenhuber, PhD,
Dr. Robert C Horan, MD,
Ellen P Madigan,
Elmina E Akwo,
Gabriel M Guevarra,
Gene D Arcy,
Helen B Ricalde,
Jacek Cieslak, PhD,
Jacqueline Mdiaz Albertini,
James C Lee, PharmD,
James P Stumpff,
Jeffrey M Watson,
John S Hartford,
Joseph George,
Julie D Bringger,
Kalavati Suvarna, PhD,
Katherine E Jacobitz,
Kevin P Foley,
Kham Phommachanh,
L Norwood,
Laurie Graham,
LCDR Debra Emerson,
Lewis K Antwi,
Linda Thai,
Lori A Holmquist,
M Pedgen,
Malgorzata G Norton, PhD,
Mariza M Jafary,
Marlene G Swider,
Mary Jeanet Mcgarry,
Megan A Haggerty,
Michelle Yclark Stuart,
Mihaly S Ligmond,
Nancy E Kirschbaum,
Nancy T Waites,
Nobuko H Katagiri,
Obinna R Echeozo,
Olga Simakova, PhD,
Omotunde O Osunsanmi,
Pankaj H Amin,
Patricia F Hughes, PhD,
Paula A Trost,
Peng Zhou,
Pete Amin (Pankaj),
Prabhu P Raju,
Priscilla M Pastrana,
Ralph A Erickson,
Ramon E Martinez,
Ranjani Prabhakara,
Rashmi Rawat, PhD,
Raymond W Brullo,
Richard Heath Coats,
Richard W Thornton,
Robert J Martin,
Robert Jennings,
Roman T Drews, PhD,
Rose Ashley,
Scott R Nichols, PhD,
Scott T Ballard,
Sean R Marcsisin,
Shafiq S Ahadi,
Simone E Pitts,
Sonya L Karsik, RAC,
Stacey S Degarmo,
Stephanie A Slater, MS,
Susan M Jackson,
Svetlana A Shestopal,
Tamala P Bogan,
Tamala P Magee,
Tania Y Hall,
Wayne E Seifert,
Zuben E Sauna, PhD
Vijaya L Simhadri's Documents
Publish Date | Document Type | Title |
---|---|---|
September, 2019 | FDA 483 | Grifols Biologicals LLC - Form 483, 2019-09-12 |
September, 2019 | FDA 483 | Grifols Biologicals LLC - Form 483, 2019-09-12 |
March, 2024 | FDA 483 | Lonza Biologics, Inc. - Form 483, 2024-03-07 |
September, 2018 | FDA 483 | Bayer HealthCare LLC - Form 483, 2018-09-21 |
March, 2024 | EIR | Lonza Biologics, Inc. - EIR, 2024-05-10 |
Experience Redica Systems’ NEW investigator profiles and dashboards
Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:
- Total inspections conducted
- 483 rate
- OAI rate
- Warning Letter rate
- Inspections by Industry, Scope, and Inspection Reason
- And much more
Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.
Talk to sales to access our investigator profiles
Loading...
Investigator Profiles Are Just the Tip of the Iceberg
Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:
Inspection Intelligence
- Pre-Approval Inspection (PAI) trends
- The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
- Latest 483s: see what the trends are across all FDA Investigators
- CFR Heatmap: Citations aggregated by Subpart by Year
Vendor Intelligence
- Full inspection histories for your vendors down to the specific site level
- All of the functionality mentioned above but isolated to just your vendors
Regulatory Intelligence
- Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
- All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more